Skip to main content

Drug Interactions between aminolevulinic acid and cobimetinib

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

aminolevulinic acid cobimetinib

Applies to: aminolevulinic acid and cobimetinib

Aminolevulinic acid sensitizes your skin to bright lights, and combining it with other medications that can also have this effect (i.E., photosensitivity) such as cobimetinib may increase the risk of a severe sunburn. In general, it is recommended that other potentially photosensitizing medications be avoided for 24 hours before and after taking aminolevulinic acid. There have also been suggestions to avoid these medications for up to 2 weeks afterwards, although it may not be feasible to interrupt some treatments for that long, especially if they are medically necessary. Check with your doctor to see if you should temporarily withhold any of your medications before and after taking aminolevulinic acid. Following treatment, you should avoid exposure of the eyes and skin to sunlight or bright indoor lights for 48 hours. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Drug and food interactions

Moderate

cobimetinib food

Applies to: cobimetinib

Grapefruit juice may increase the blood levels and effects of certain medications such as cobimetinib. You may want to limit your consumption of grapefruit and grapefruit juice during treatment with cobimetinib. However, if you have been regularly consuming grapefruit or grapefruit juice with cobimetinib, do not alter the amounts of these products in your diet without first talking to your doctor or other healthcare professional. Contact your doctor if your condition changes or you experience increased side effects. Orange juice is not expected to interact.

Switch to professional interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer